Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Iveric Bio, an Astellas company, reported on Sept. 18 positive 24-month topline results from the Phase III GATHER2 trial of Izervay (avacincaptad pegol), its treatment for geographic atrophy (GA) s...
Mati Therapeutics, of Austin, Texas, reported Sept. 12 that it had completed a 10 thousand square foot facility in Bryan, Texas, to manufacture the company’s Evolute sustained drug delivery platfor...
Swiss company Novartis reported Sept. 15 that its shareholders had approved its spinoff of Sandoz, its generics and biosimilars business. The target date for the spinoff is Oct. 4. Sandoz is a lead...
Eye surgeons swapped their scrubs for boxing robes at the 2023 congress of the European Society of Cataract and Refractive Surgeons, as they took part in the society’s high-profile battle against s...
NeoLight announced Sept. 12 that the US FDA had cleared the expanded fluorescein angiography (FA) capabilities of the company’s portable retinal camera Icon Go. The Scottsdale, Arizona, company sai...
Precision Dropper, of Twin Falls, Idaho, on Sept. 15 introduced its universal adapter for eye drop bottles, designed to increase patient comfort and reduce waste when administering topical ocular m...
Nanoscope Therapeutics, of Dallas, announced Sept. 21 that it had appointed Samuel Barone, MD, as chief medical officer. Barone was most recently chief medical officer at Gemini Therapeutics, prior...
Ophthalmic manufacturer revenue in Q2-2023 totaled $11.4 billion. Most public companies reported above-average revenue in Q2-2023 compared with the past three years, while four public companies had...
US ophthalmologists reported that ophthalmic procedures decreased 4.9 percent in Q2-2023 compared with the same quarter in 2022, according to Market Scope’s latest survey. Year-over-year performanc...
Bausch + Lomb announced Sept. 12 the US launch of Miebo (perfluorohexyloctane ophthalmic solution) for dry eye disease. The US FDA approved Miebo in May for dosing four times daily. Bausch + Lomb a...
Outlook Therapeutics reported on Aug. 30 that the US FDA had issued a complete response letter to the company’s biologics license application (BLA) for Lytenava, an ophthalmic formulation of bevaci...
Iridex announced Aug. 29 that it would undergo a review of strategic alternatives, with Piper Sandler acting as financial advisor. The Mountain View, California, ophthalmic laser company said there...
The US FDA granted four clearances through the ophthalmic device division using the 510(k) pathway in August 2023, according to the agency’s database. RxSight received clearance for a new IOL injec...
We will have multiple representatives attending the AAO meeting from Nov. 3-6 at the Moscone Center in San Francisco. To schedule a time to meet with us, please email Matthew Douty at matt@market-s...
BVI Medical announced Sept. 6 that it had acquired Medical Mix, a leading supplier of ophthalmic surgical devices in Spain and Portugal. No financial details were provided. Medical Mix, of Barcelon...
The US FDA reported Sept. 12 that it had issued warning letters to eight companies for manufacturing or marketing unapproved eye drug products, expanding the list of companies that the FDA has targ...
Brim Biotechnologies, of Taiwan, led recent ophthalmic fundraising efforts with a $45.8 million rights issue to advance its lead dry eye candidate. Funding announced in the past four weeks totaled ...
The California Institute for Regenerative Medicine (CIRM) announced July 27 that it had awarded a $12.4 million grant to Regenerative Patch Technologies (RPT) to support a Phase IIb clinical trial ...
UK life sciences investment firm Syncona reported on Sept. 11 that Novartis had decided to discontinue development of geographic atrophy (GA) gene therapy candidate GT005, which it acquired in Dece...
The US Federal Trade Commission (FTC) will allow Amgen to acquire Horizon Therapeutics, after Amgen agreed in a consent order to several conditions related to how it will market its newly purchased...
EarliTec Diagnostics reported Sept. 5 that The Journal of the American Medical Association (JAMA) had released study results for its eye tracking system for autism in two of its publications. The s...
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease. Company Location About 3SBio Shenyang, China The company lists 31 products in development, i...
Apellis Pharmaceuticals, maker of the intravitreal drug Syfovre (pegcetacoplan) for geographic atrophy (GA), announced Aug. 29 that it would lay off about 225 employees—a quarter of its workforce—a...
Market Scope estimates that the ophthalmic diagnostic equipment market will generate $3.7 billion in total revenue in 2023, and the market will grow to $4.4 billion by 2028, for a compound annual g...
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.